RELEVANCE - RWE Study in Unresectable Non-Small Cell Lung Cancer (Stage III) in Canada

NCT05933044 · clinicaltrials.gov ↗

COMPLETED

Status

662

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Durvalumab

Sponsor

AstraZeneca